Second Malignancies in Philadelphia-negative Myeloproliferative
Neoplasms–Single-center Experience

J 2014

Second Malignancies in Philadelphia-negative Myeloproliferative Neoplasms–Single-center Experience

KISSOVÁ, Jarmila; Petra OVESNÁ; Miroslav PENKA; Alena BULIKOVÁ; Igor KISS et al.

Základní údaje

Originální název

Second Malignancies in Philadelphia-negative Myeloproliferative Neoplasms–Single-center Experience

Autoři

KISSOVÁ, Jarmila; Petra OVESNÁ ; Miroslav PENKA; Alena BULIKOVÁ a Igor KISS

Vydání

ANTICANCER RESEARCH, ATHENS, INT INST ANTICANCER RESEARCH, 2014, 0250-7005

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.826

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/14:00075664

Organizační jednotka

Lékařská fakulta

UT WoS

000335545900059

Klíčová slova anglicky

Second malignancies; hydroxyurea; myeloproliferative neoplasm; skin cancer

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 13. 2. 2015 15:54, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

The aim of this work was to retrospectively analyze patients with Philadelphia-negative myeloproliferative neoplasms through evaluation of frequency and characteristics of second malignancies (other than acute leukaemia and myelodysplastic syndrome). Patients and Methods: Records of 172 patients were reviewed; an analysis was performed on data from 66 patients treated with hydroxyurea, 105 patients treated with other cytoreductive therapy, and 25 patients without treatment. Results: A higher occurrence of second malignancies was found in the group treated with hydroxyurea (7.6%; other cytoreduction: 1.2%; without therapy: 0). After a median follow-up of 89 months in the hydroxyurea group, 13 patients developed second cancer during hydroxyurea therapy, located on the skin (68.75%) and other sites (31.25%). Conclusion: The incidence of second malignancies during hydroxyurea therapy in our cohort patient was significantly higher than the incidence of malignancies in the Czech population of corresponding age.

Citovat

KISSOVÁ, Jarmila; Petra OVESNÁ; Miroslav PENKA; Alena BULIKOVÁ a Igor KISS. Second Malignancies in Philadelphia-negative Myeloproliferative Neoplasms–Single-center Experience. ANTICANCER RESEARCH. ATHENS: INT INST ANTICANCER RESEARCH, 2014, roč. 34, č. 5, s. 2489-2496. ISSN 0250-7005.

@article{1185406,
   author = {Kissová, Jarmila and Ovesná, Petra and Penka, Miroslav and Buliková, Alena and Kiss, Igor},
   article_location = {ATHENS},
   article_number = {5},
   keywords = {Second malignancies; hydroxyurea; myeloproliferative neoplasm; skin cancer},
   language = {eng},
   issn = {0250-7005},
   journal = {ANTICANCER RESEARCH},
   title = {Second Malignancies in Philadelphia-negative Myeloproliferative Neoplasms–Single-center Experience},
   volume = {34},
   year = {2014}
}

TY  - JOUR
ID  - 1185406
AU  - Kissová, Jarmila - Ovesná, Petra - Penka, Miroslav - Buliková, Alena - Kiss, Igor
PY  - 2014
TI  - Second Malignancies in Philadelphia-negative Myeloproliferative Neoplasms–Single-center Experience
JF  - ANTICANCER RESEARCH
VL  - 34
IS  - 5
SP  - 2489-2496
EP  - 2489-2496
PB  - INT INST ANTICANCER RESEARCH
SN  - 02507005
KW  - Second malignancies
KW  - hydroxyurea
KW  - myeloproliferative neoplasm
KW  - skin cancer
N2  - The aim of this work was to retrospectively analyze patients with Philadelphia-negative myeloproliferative neoplasms through evaluation of frequency and characteristics of second malignancies (other than acute leukaemia and myelodysplastic syndrome). Patients and Methods: Records of 172 patients were reviewed; an analysis was performed on data from 66 patients treated with hydroxyurea, 105 patients treated with other cytoreductive therapy, and 25 patients without treatment. Results: A higher occurrence of second malignancies was found in the group treated with hydroxyurea (7.6%; other cytoreduction: 1.2%; without therapy: 0). After a median follow-up of 89 months in the hydroxyurea group, 13 patients developed second cancer during hydroxyurea therapy, located on the skin (68.75%) and other sites (31.25%). Conclusion: The incidence of second malignancies during hydroxyurea therapy in our cohort patient was significantly higher than the incidence of malignancies in the Czech population of corresponding age.
ER  -

KISSOVÁ, Jarmila; Petra OVESNÁ; Miroslav PENKA; Alena BULIKOVÁ a Igor KISS. Second Malignancies in Philadelphia-negative Myeloproliferative Neoplasms–Single-center Experience. \textit{ANTICANCER RESEARCH}. ATHENS: INT INST ANTICANCER RESEARCH, 2014, roč.~34, č.~5, s.~2489-2496. ISSN~0250-7005.

Přehled o publikaci